This business information is not released now.


Back
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.


BrightPath Biotherapeutics Co., Ltd.
【Field/Business】
Pharmaceutical/Drug Discovery


last update:2019/6/13
Profile

Delegates :
Kenichi Nagai, President and CEO


Incorporated :
May   8 , 2003

Paid in Capital :
5427 Million yen  Increased due to IPO and financing after IPO

Employees :
42 人

Address :
2-2-4, Kojimachi, Chiyoda-ku TOKYO
〒102-0083

TEL/FAX :
+81-3-5840-7697 / +81-3-5840-7716

URL:
https://www.brightpathbio.com/english/index.html

Attachment :

Mission/Background :
BrightPath Biotherapeutics, formerly known as GreenPeptide, is a Japan-based clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapeutics. Our pipeline includes cancer peptide vaccine, rejuvenated cell therapy, and immuno-modulator antibodies. Our basic business model covers research and early clinical development, followed by out-licensing to pharmaceutical companies.

Technology & Business
BrightPath is targeting to research and development of promising drug candidate in the immuno-oncology area. We are conducting clinical studies of novel cancer peptide vaccine, Phase 2 study of GRN-1201 in the US.
Our next target is fully-personalized cancer vaccine, so we are conducting collaborative research to develop a methodology to identify a target set of neoantigens from the cancer mutations (mutated gene sequence data) with National Cancer Center Japan, Kanagawa Cancer Center, University of Tokyo, and Mie University.
Regarding cell therapy, we are conducting collaborative research of iPS-NKT cell therapy with RIKEN.
Products & Service
Products & Service Name
Stage
Outline
Milestone
GRN-1201 (HLA-A02 restricted cancer peptide vaccine)
Phase2
Indication: melanoma, non-small cell lung cancer (in combination with immune checkpoint inhibitor)
To acquire effective data in combination of an immune checkpoint antibody
iPS-NKT cell therapy
Preclinical
Indication: Head and neck cancer
To initiate investigator initiated clinical trial












Highlights
(GRN-1201)
2015 Start of phase I for malignant melanoma in the U.S.
2017 Start of phase II in combination with immune checkpoint inhibitor for NSCLC in the U.S.
(iPS-NKT)
2018 Start of collaborative research with RIKEN
(Fully Personalized Neoantigen Vaccine)
2017 Start of collaborative research with National Cancer Center Japan
2018 Start of collaborative research with University of Tokyo and Kanagawa Cancer Center
Start of collaborative research with Mie University
Hot news

Alliance strategy
Brightpath is seeking out-licensing partners regarding our promising pipeline and in-licensing/co-development partners to enhance our scientific basis in cancer immunotherapy.

 
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.